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Abstract
We present CoronaHiT, a platform and throughput flexible method for sequencing SARS-CoV-2 genomes (≤ 96 on
MinION or > 96 on Illumina NextSeq) depending on changing requirements experienced during the pandemic.
CoronaHiT uses transposase-based library preparation of ARTIC PCR products. Method performance was
demonstrated by sequencing 2 plates containing 95 and 59 SARS-CoV-2 genomes on nanopore and Illumina
platforms and comparing to the ARTIC LoCost nanopore method. Of the 154 samples sequenced using all 3
methods, ≥ 90% genome coverage was obtained for 64.3% using ARTIC LoCost, 71.4% using CoronaHiT-ONT and
76.6% using CoronaHiT-Illumina, with almost identical clustering on a maximum likelihood tree. This protocol will
aid the rapid expansion of SARS-CoV-2 genome sequencing globally.
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Background
The COVID-19 pandemic caused by the SARS-CoV-2
virus began late 2019 in Wuhan, China, and has now
spread to virtually every country in the world, with tens
of millions of confirmed cases and millions of deaths [1].
Key to the control of the pandemic is understanding the
epidemiological spread of the virus at global, national
and local scales [2]. Whole-genome sequencing of
SARS-CoV-2 is likely to be the fastest and most accurate
method to study virus epidemiology as it spreads. We
are sequencing SARS-CoV-2 as part of the COVID-19
Genomics UK (COG-UK) consortium, a network of
academic and public health institutions across the UK
brought together to collect, sequence and analyse whole
genomes to fully understand the transmission and evolu-
tion of this virus [3]. The SARS-CoV-2 genome was first
sequenced in China using a metatranscriptomic ap-
proach [4]. This facilitated the design of tiling PCR ap-
proaches for genome sequencing, the most widely used
of which is the ARTIC Network [5] protocol. Consensus
genome sequences are typically made publicly available
on the Global Initiative on Sharing Avian Influenza Data
(GISAID) database [6]. This has enabled real-time public
health surveillance of the spread and evolution of the
pandemic through interactive tools such as NextStrain
[7]. The ARTIC network protocol was designed for
nanopore technology (Oxford Nanopore Technologies),
enabling rapid genome sequencing for outbreak re-
sponse. The method was originally capable of testing
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only 23 samples plus a negative control on a flowcell;
however, with the recent release of the Native Barcoding
Expansion 96 kit by ONT, 11–95 samples plus a nega-
tive control can be sequenced on a flowcell using the
ARTIC LoCost V3 method [8]. A platform agnostic
method is required to provide flexible throughput on
Illumina or nanopore that allows low-cost sequencing of
10s to 100 s of viral genomes depending on (1) changing
requirements as the pandemic peaks and troughs and (2)
the turnaround time required e.g. routine weekly vs
rapid outbreak sequencing. Here we describe a flexible
protocol, Coronavirus High Throughput (CoronaHiT),
which allows for up to 95 samples, plus a negative con-
trol to be multiplexed on a single MinION flowcell or al-
ternatively, by switching barcodes, over 384 samples on
Illumina. We demonstrate CoronaHiT’s performance on
95 and 59 SARS-CoV-2 genomes on MinION and Illu-
mina NextSeq for routine and rapid outbreak response
runs, respectively, and compare to the ARTIC LoCost
protocol.
Methods
Patient samples and RNA extraction
One hundred fifty-four SARS-CoV-2 positive samples
from patients with suspected COVID-19 were collected
from four laboratories in East Anglia—(1) the Cytology
Department, NNUH, Norwich, UK, (2) Microbiology
Department, NNUH, Norwich, UK, (3) the Bob Cham-
pion Research & Education Building (BCRE), University
of East Anglia, Norwich, UK and (4) Ipswich Public
Health Laboratory, Ipswich, UK.
Out of the 154 samples, 95 were collected from the
Cytology Department and tested using the Roche Cobas®
8800 SARS-CoV-2 system according to the manufac-
turer’s instructions. Twenty-eight samples were collected
from the Microbiology Department which were tested
using either the Hologic Panther System Aptima® SARS-
CoV-2 assay (n = 25) or Altona Diagnostics RealStar®
SARS-CoV-s RT-PCR Kit 1.0 according to the manufac-
turer’s instructions (n = 3). Seven samples were collected
from the BCRE where RNA was extracted using the
MagMAX™ Viral/Pathogen II Nucleic Acid Isolation kit
(Applied Biosystems) according to the manufacturer’s
instructions and the KingFisher Flex system (Thermo-
Fisher), and the presence of SARS-CoV-2 was deter-
mined using the 2019-nCoV CDC assay on the
QuantStudio 5 (Applied Biosystems). Twenty-four sam-
ples were collected from the Ipswich Public Health La-
boratory where samples were tested using the
AusDiagnostics SARS-CoV-2, Influenza and RSV 8-well
panel. RNA was extracted from swab samples using ei-
ther the AusDiagnostics MT-Prep (AusDiagnostics) or
QIAsymphony (Qiagen) platforms according to the
manufacturer’s instructions before being tested by the
AusDiagnostics assay.
Viral transport medium from positive swabs (stored at
4 °C) was collected for all samples run on the Roche
Cobas®, Hologic Panther System and Altona RealStar®. In
all other cases excess RNA was collected (frozen at −
80 °C). Excess positive SARS-CoV-2 inactivated swab
samples (200 μl viral transport medium from nose and
throat swabs inactivated in 200 μl Zymo DNA/RNA
shield and 800 μl Zymo viral DNA/RNA buffer) were
collected from Cytology and the Microbiology Depart-
ments. SARS-CoV-2 positive RNA extracts (~ 20 μl)
were collected from Ipswich Public Health Laboratory
and the BCRE as part of the COG-UK Consortium pro-
ject (PHE Research Ethics and Governance Group R&D
ref. no NR0195). RNA was extracted from inactivated
swab samples using the Quick DNA/RNA Viral Mag-
bead kit from step 2 of the DNA/RNA purification
protocol (Zymo).
The lower of the cycle thresholds (Ct) produced by the
two SARS-CoV-2 assays in the Roche, AusDiagnostics,
Altona Diagnostics and CDC assays were used to deter-
mine whether samples required dilution before sequen-
cing according to the ARTIC protocol. The Aptima
SARS-CoV-2 assay on the Hologic Panther System does
not provide a Ct value but rather a combined fluores-
cence signal for both targets in relative light units
(RLUs); therefore, all samples tested by the Hologic Pan-
ther were processed undiluted in the ARTIC protocol.
ARTIC SARS-CoV-2 multiplex tiling PCR
cDNA and multiplex PCR reactions were prepared fol-
lowing the ARTIC nCoV-2019 sequencing protocol V3
(LoCost) [8]. Dilutions of RNA were prepared when re-
quired based on Ct values following the guidelines from
the ARTIC protocol.
V3 CoV-2 primer scheme [9] was used to perform the
multiplex PCR for SARS-CoV-2 according to the ARTIC
protocol [8]. For the ARTIC multiplex PCR, 65 °C was
chosen as the annealing/extension temperature, and due
to variable Ct values, all samples were run for 35 cycles
in the two multiplex PCRs.
CoronaHiT-ONT library preparation
Libraries were prepared using a novel modified Illumina
DNA prep tagmentation approach (formerly called Nex-
tera DNA Flex Illumina Library Prep) [10, 11]. Primers
with a 3′ end compatible with the Nextera transposon
insert and a 24 bp barcode at the 5′ end with a 7 bp spa-
cer were used to PCR barcode the tagmented ARTIC
PCR products. The barcode sequences are from the PCR
Barcoding Expansion 1-96 kit (EXP-PBC096, Oxford
Nanopore Technologies). Symmetrical dual barcoding
was used, i.e. the same barcode added at each end of the
Baker et al. Genome Medicine           (2021) 13:21 Page 2 of 11
PCR product and up to 96 samples could be run to-
gether using this approach or 95 if a negative control is
included (Additional file 1: Table S1).
ARTIC PCR products were diluted 1:5 (2.5 μl Pool 1,
2.5 μl Pool 2 and 20 μl PCR grade water). Tagmentation
was performed as follows: 0.5 μl TB1 Tagmentation Buf-
fer 1, 0.5 μl BLT Bead-Linked Transposase (both con-
tained in Illumina® DNA Prep, (M) Tagmentation
Catalogue No 20018704) and 4 μl PCR grade water was
made as a master mix scaled to sample number. On ice,
5 μl of tagmentation mix was added to each well of a
chilled 96-well plate. Next, 2 μl of diluted PCR product
was pipette mixed with the 5 μl tagmentation mix. This
plate was sealed and briefly centrifuged before incuba-
tion at 55 °C for 15 min in a thermal cycler (heated lid
65 °C) and held at 10 °C.
PCR barcoding was performed using Kapa 2G Robust
PCR kit (Sigma Catalogue No. KK5005) as follows: 4 μl
Reaction buffer (GC), 0.4 μl dNTP’s, 0.08 μl Kapa 2G Ro-
bust Polymerase and 7.52 μl PCR grade water per sample
were mixed and 12 μl was added to each well in a new
96-well plate. One microliter of the appropriate barcode
pair (Additional file 1: Table S1) at 10 μM was added to
each well. Finally, the 7 μl of Tagmentation mix was
added, making sure to transfer all the beads. PCR reac-
tions were run at 72 °C for 3 min, 95 °C for 1 min,
followed by 14 cycles of 95 °C for 10 s, 55 °C for 20 s and
72 °C for 1 min. Following PCR, 2 μl of each sample was
pooled and 40 μl of this pool was bead washed with
36 μl (0.8X) AMPure XP beads (2 washes in 200 μl 70%
ethanol) for the routine samples. For the rapid response
run, 100 μl of the pool was washed with 60 μl (0.6X)
AMPure XP. Pools were eluted in 20 μl of EB (Qiagen
Catalogue No. 19086). The barcoded pool was quantified
using Qubit High Sensitivity kit (Catalogue No.
Q32851).
A nanopore sequencing library was then made, largely
following the SQK-LSK109 protocol. The end-prep reac-
tion was prepared as follows: 7 μl Ultra II end prep buf-
fer, 3 μl Ultra II end prep enzyme mix, 40 μl nuclease
free water and 10 μl of washed barcoded pool from the
previous step (final volume 60 μl). The reaction was in-
cubated at room temperature for 15 min and 65 °C for
10 min, followed by a hold at 4 °C for at least 1 min. This
was bead-washed using 60 μl of AMPure Beads (1X) and
two 200 μl 70% ethanol washes and eluted in 61 μl nu-
clease free water. The end-prepped DNA was taken for-
ward to the adapter ligation as follows: 30 μl end-
prepped pool from previous step (~ 60 ng), 30 μl nucle-
ase free water, 25 μl LNB (ONT), 10 μl NEBNext Quick
T4 Ligase and 5 μl AMX (ONT) was mixed and incu-
bated at room temperature for 20 min. After the incuba-
tion, the full volume was washed with 40 μl AMPure XP
beads and 2 consecutive 250 μl SFB (ONT) washes with
resuspension of beads both times and this was eluted in
15 μl of EB (ONT). The final library was quantified with
Qubit High Sensitivity and size checked on a Tapesta-
tion with D5000 tape. 12 μl (~ 30–50 ng) was used for
flowcell loading, with the addition of 37.5 μl SQB and
25.5 μl LB.
CoronaHiT-Illumina library preparation
PCR products were tagmented and barcoded as de-
scribed for the CoronaHiT-ONT library preparation;
however, standard Nextera XT Index Kit indexes were
used (Sets A to D for up to 384 combinations, Illumina
Catalogue No’s FC-131-2001, FC-131-2002, FC-131-
2003 and FC-131-2004). Unique dual indexes should be
used with patterned flowcells instead, to mitigate index
hopping (IDT for Illumina Nextera DNA Unique Dual
Indexes Sets A-D, Illumina Catalogue No’s 20027213,
20027214, 20027215, 20027216). The PCR master mix
was adjusted and water removed to add 2 μl each of the
P7 and P5 primers. Five microliters of each barcoded
sample was pooled (without quantification), and 100 μl
of the library pool was size selected with 0.8X AMPure
XP beads (80 μl), with final elution in 50 μl EB (10 mM
Tris-HCl). The barcoded pool was sized on an Agilent
Tapestation D5000 tape and quantified using Quanti-
Fluor® ONE dsDNA System (Promega, WI, USA) and
the molarity calculated. The Illumina library pool was
run at a final concentration of 1.5 pM on an Illumina
Nextseq500 instrument using a Mid Output Flowcell
(NSQ® 500 Mid Output KT v2 (300 CYS) Illumina Cata-
logue FC-404-2003) following the Illumina recom-
mended denaturation and loading recommendations
which included a 1% PhiX spike (PhiX Control v3 Illu-
mina Catalogue FC-110-3001).
ARTIC LoCost protocol Nanopore library preparation
After ARTIC multiplex PCR, library preparation was
performed using the nCoV-2019 sequencing protocol v3
(LoCost) V3 [8]. Briefly, PCR Pool 1 and 2 were pooled
for each sample and diluted 1 in 10 (2.5 μl Pool 1, 2.5 μl
Pool 2 and 45 μl nuclease free water) and end-prepped
as follows: 1.2 μl Ultra II end prep buffer, 0.5 μl Ultra II
end prep enzyme mix, 3.3 μl PCR dilution from previous
step and 5 μl nuclease free water (final volume 15 μl).
The reaction was incubated at room temperature for 15
min and 65 °C in a thermocycler for 15 min and incu-
bated on ice for 1 min. Native barcode ligation was pre-
pared in a new plate: 0.75 μl end-prepped DNA, 1.25 μl
native barcode, 5 μl Blunt/TA Ligase Master Mix, and
3 μl nuclease free water (final volume 10 μl). The reac-
tion was incubated at room temperature 20 min and
65 °C in a thermocycler for 10 min and incubated on ice
for 1 min. Amplicons were pooled together (2 μl for 95
samples and 5 μl for 59 samples) and underwent a 0.4X
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AMPure bead wash with two 250 μl SFB washes and one
70% ethanol wash. DNA was eluted in 30 μl of Qiagen
EB. Adapter ligation was performed on the full volume
(30 μl barcoded amplicon pool, 5 μl Adapter Mix II
(ONT), 10 μl NEBNext Quick Ligation Reaction Buffer
(5X), 5 μl Quick T4 DNA Ligase). The ligation reaction
was incubated at room temperature for 20 min and 1X
bead washed (50 μl AMPure XP beads) with 250 μl SFB
two times. The library was eluted in 15 μl of elution buf-
fer (ONT) and quantified. 15 ng of the adapted library
was used for final loading.
Nanopore sequence analysis
Basecalling was performed using Guppy v.4.2.2 (Oxford
Nanopore Technologies) in high accuracy mode (model
dna_r9.4.1_450bps_hac), on a private OpenStack cloud
at Quadram Institute Bioscience using multiple Ubuntu
v18.04 virtual machines running Nvidia T4 GPU.
The CoronaHiT-ONT sequencing data were demulti-
plexed using guppy_barcoder (v4.2.2) with a custom ar-
rangement of the barcodes [12] and with the option
‘require_barcodes_both_ends’ and a score of 60 at both
ends to produce 95 FASTQ files (94 SARS-CoV-2 sam-
ples and 1 negative control) and 61 FASTQ files (59
SARS-CoV-2 samples and 2 negative control) for the
routine and rapid response runs, respectively. The ARTI
C ONT sequencing data were demultiplexed using
guppy_barcoder (v4.2.2) with the option ‘require_bar-
codes_both_ends’ and a score of 60 at both ends to pro-
duce 95 FASTQ files (94 SARS-CoV-2 samples and 1
negative control) and 61 FASTQ files (59 SARS-CoV-2
samples and 2 negative control) for the routine and
rapid response runs, respectively.
The downstream analysis was performed using a copy
of the ARTIC pipeline (v1.1.3) as previously described
[13] to generate a consensus sequence for each sample
in FASTA format. The pipeline includes the following
main steps: the input reads were filtered based on reads
length (ARTIC, 400–700; CoronaHiT, 150–600), and
mapped to the Wuhan-Hu-1 reference genome (acces-
sion MN908947.3) using minimap2 (v 2.17-r941). The
mapped bases in BAM format were trimmed off in pri-
mer regions by the ARTIC subcommand align_trim for
ARTIC LoCost data. For CoronaHiT-ONT data, the
pipeline was modified to use the subcommand samtools
ampliconclip (v 1.11) at the primer trimming step [14].
The trimmed reads were then used for variant calling
with medaka (v 1.2.0) and longshot (v 0.4.1). The final
consensus was generated from a filtered VCF file and a
mask file of positions with either a depth of coverage
lower than 20 or a SNP in an amplifying primer site.
The metrics and results of all experiments are available
in Additional file 1: Table S2a and S2b and are sum-
marised in Table 1.
Illumina sequence analysis
Additional samples, not reported in this study, were in-
cluded on Illumina NextSeq runs. The raw reads were
demultiplexed using bcl2fastq (v2.20) (Illumina Inc.) to
produce 311 FASTQ files for the run with the routine
samples (112 SARS-CoV-2 samples and 3 negative con-
trols) and the run with the rapid response samples (247
SARS-CoV-2 samples, 4 negative controls, and 2 positive
controls) with only the relevant samples analysed in this
paper. The reads were used to generate a consensus se-
quence for each sample using an adapted open source
pipeline [15]. Briefly, the reads had adapters trimmed
Table 1 Summary statistics for each sequencing experiment













No. of samples 95 95 95 59 59 59
Run time (h) 30 30 25.4 18 18 24.4
Yielded bases (Gb) 10.3 8.5 43.9* 6.3 4.8 48.6*
Bases deplexed (Gb) 9.6 8.0 15.7 5.7 4.5 7.3
Reads sequenced (> Q7) 24764627 15733349 113756312 13044532 8824469 53678322
Average PHRED score 13.47 13.11 33.15 13.2 12.98 33.48
Average coverage (X) 1145X 1719X 4649X 1104X 1421X 3010X
Standard deviation of coverage
(X)
698X 1683X 4352X 439X 1145X 3496X
Average read length (bases) 374 448 135 413 457 135
Average (median) mapped length 205.24 (195) 386 (386) 134.63 (150) 241.25 (244) 383.88 (385) 131.43 (150)
Samples passing GISAID QC 66 59 74 44 40 44
Sample specific metrics are available in Additional file 1: Table 2a and b
*The CoronaHiT-Illumina total yield includes non-relevant samples on the sequencing run, while the deplexed yield only relates to relevant samples
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with TrimGalore [16] and were aligned to the Wuhan-
Hu-1 reference genome (accession MN908947.3) using
BWA-MEM (v0.7.17) [17]; the ARTIC amplicons were
trimmed and a consensus built using iVAR (v.1.2.3) [18].
Quality control
The COG-UK consortium defined a consensus sequence
as passing COG-UK quality control if greater than 50%
of the genome was covered by confident calls or there
was at least 1 contiguous sequence of more than 10,000
bases and with no evidence of contamination. This is
regarded as the minimum amount of data to be phylo-
genetically useful. A confident call was defined as having
a minimum of 10X depth of coverage for Illumina data
and 20X depth of coverage for Nanopore data. If the
coverage fell below these thresholds, the bases were
masked with Ns. Low quality variants were also masked
with Ns. The QC threshold for inclusion in GISAID was
higher, requiring that greater than 90% of the genome
was covered by confident calls with no evidence of
contamination.
Phylogenetic analysis
For each sample sequenced in 3 separate experiments
(CoronaHiT-ONT, CoronaHiT-Illumina, ARTIC-ONT),
a phylogeny was generated from all of the consensus ge-
nomes (n = 216 for the routine samples and n = 132 for
the rapid response samples) passing GISAID QC over all
experiments (n = 72 out of 95, and n = 44 out of 59). A
multiple FASTA alignment was created by aligning all
samples to the reference genome MN908947.3 with
MAFFT v7.470. A maximum likelihood tree was esti-
mated with IQTREE2 (v2.0.4) [19] under the HKY
model [20], collapsing branches smaller than 10−7 into a
polytomy. SNPs in the multiple FASTA alignment were
identified using SNP-sites (v2.5.1) [21], and the tree was
visualised with FigTree (v1.4.4) [22].
Results
A novel library preparation method, CoronaHiT, was de-
veloped for SARS-CoV-2 genome sequencing, which
combines a cheap transposase-based introduction of
adapters (Illumina Nextera) with symmetric PCR bar-
coding of up to 96 samples (or 95 samples with a nega-
tive control) on a MinION. Alternatively, if higher
throughput is needed, the barcodes can be switched for
Illumina sequencing. For ONT sequencing, Nextera
adapter complementary primer sequences were added to
ONT PCR barcodes and used to barcode ARTIC PCR
products (Fig. 1) as described in the methods. For Illu-
mina sequencing, the method is a streamlined and
cheaper version of standard Illumina library prepara-
tions. CoronaHiT does not require individual sample
washes and allows samples to be processed uniformly
without quantification or normalisation as with the
ARTIC LoCost method.
The CoronaHiT method was tested by multiplexing 95
SARS-CoV-2 routine COG-UK samples plus a blank
(hereinafter referred to as the Routine Samples) on a
MinION flowcell and on an Illumina NextSeq run.
Fig. 1 Workflow of CoronaHiT-ONT library preparation
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Another 59 samples, including 18 query outbreak sam-
ples, plus blanks (hereinafter referred to as the Rapid Re-
sponse samples) were rapidly sequenced (within 24 h of
receipt, with results available the following day) on a
second flowcell, as well as on Illumina NextSeq. All sam-
ples were also sequenced using the ARTIC LoCost li-
brary preparation protocol on the MinION for
comparison. For the routine samples, 30 h of sequencing
data was used for both CoronaHiT-ONT and ARTIC
LoCost, and for the rapid response set, 18 h was used;
the full dataset was used for both CoronaHiT-Illumina
runs. The different methods produced different amounts
of demultiplexed data. For the routine samples,
CoronaHiT-ONT yielded 9.6 Gbases of sequence data,
ARTIC LoCost sequencing produced 8.0 Gbases of data
and CoronaHiT-Illumina yielded 15.7 Gbases giving on
average 1145X, 1719X and 4649X coverage per sample
(Table 1). For the rapid response dataset, CoronaHiT-
ONT produced 5.7 Gbases, ARTIC LoCost 4.5 Gbases
and CoronaHiT-Illumina 7.3 Gbases resulting in 1104X,
1421X and 3010X coverage per sample respectively.
Both CoronaHiT-ONT runs had less variation in cover-
age between samples compared to the ARTIC LoCost
runs, with lower standard deviation relative to the mean
(Table 1). The lower coverage for CoronaHiT-ONT
compared to ARTIC is related to the shorter read
lengths and the increased proportion of barcode/adapter
sequence in each read and, hence, the reduced mappable
region of each read.
Taking all the genomes which passed COG-UK QC,
the CoronaHiT-Illumina sequencing runs produced the
shortest mappable mean read length at 135 and 131
bases for the routine samples and rapid response sam-
ples respectively, just short of the maximum 150 bases
for the PE 151 chemistry; ARTIC LoCost produced 386
and 384 bases, and CoronaHiT-ONT sequencing pro-
duced mappable mean read lengths of 205 and 241
bases. The shorter read lengths for CoronaHiT are re-
lated to the use of bead-linked transposases for tagmen-
tation, resulting in the removal of the ends of the ARTI
C PCR products. The introduction of a 0.6X bead wash
for the rapid response CoronaHiT-ONT run (instead of
the 0.8X bead wash for the routine run) resulted in the
longer mapped reads and contributed to a reduction in
the difference in average coverage between CoronaHiT
and ARTIC (from 1145x vs 1719x in routine run drop-
ping to 1104X vs 1421X in the rapid response run, with
similar ratios of raw data produced by the methods in
the two runs).
The demultiplexing steps for CoronaHiT-ONT were
different from those used for ARTIC ONT sequencing
as described in the methods section. Comparing the
nanopore sequencing methods for the routine samples,
74.7% and 81.9% of reads were demultiplexed
successfully for CoronaHiT-ONT and ARTIC LoCost
respectively when only reads with a PHRED (quality)
score above Q7 are considered; for the rapid response
set, 69.6% and 71.6% were demultiplexed for
CoronaHiT-ONT and ARTIC LoCost. The rest of the
reads were unassigned, due to an inability to detect the
barcode sequences at both ends of the reads. The nega-
tive controls contained zero mapping reads to SARS-
CoV-2 for all nanopore datasets. The Illumina routine
dataset had mapped reads; however, the vast majority
were primer dimers (range of 0–4 SARS-CoV-2 reads >
40 bp mapped out of the 3 negative controls).
Poor quality consensus genomes were generally associ-
ated with a lower SARS-CoV-2 viral load in the clinical
samples i.e. higher RT-qPCR Ct values (generally above
Ct 32) were more likely to fail COG-UK and GISAID
quality control thresholds. For all methods, the number
of Ns increased significantly in samples with a Ct above
32, which equates to approx. 100 viral genome copies in
the PCR reaction (Fig. 2). Positions of Ns (missing or
masked bases) within the consensus genomes are seen in
Additional file 2: Figure S1–S6—the three ARTIC PCR
primer dropout areas [23] are clearly visible. Comparing
the routine samples with a Ct of 32 or below (n = 65; Cts
for most rapid response samples were unknown), the
mean (median) number of Ns was 815 (121) for ARTIC
LoCost, 111 (47) for CoronaHiT-Illumina and 682 (339)
for CoronaHiT-ONT. If all samples are included for the
routine set (including higher Ct samples), then the num-
ber of Ns increases substantially to a mean (median) of
1635 (121) bases for ARTIC LoCost, 688 (53) for
CoronaHiT-Illumina and 1504 (359) for CoronaHiT-
ONT.
The number of samples passing the COG-UK QC cri-
teria was 73 for ARTIC LoCost, 76 for CoronaHiT-ONT
and 78 for CoronaHiT-Illumina in the routine set and
44 for ARTIC LoCost and 48 for both CoronaHiT-ONT
and CoronaHiT-Illumina in the rapid response set. The
stricter GISAID QC criteria reduce the number of sam-
ples passing QC, with the CoronaHiT method outper-
forming ARTIC LoCost. For the routine samples, 59
samples passed for ARTIC LoCost, 66 passed for
CoronaHiT-ONT and 74 passed for CoronaHiT-
Illumina and for the rapid response set 40 passed for
ARTIC LoCost, and 44 passed for both CoronaHiT-
ONT and CoronaHiT-Illumina. Overall, the pass rate
was 64.3% for ARTIC LoCost, 71.4% for CoronaHiT-
ONT and 76.6% for CoronaHiT-Illumina. When consid-
ering higher viral load samples with a known Ct of 32 or
below, the pass rate for both GISAID and COG-UK QC
was higher, with 89.2% passing for ARTIC LoCost and
95.2% and 97.6% passing for CoronaHiT-ONT and
CoronaHiT-Illumina, respectively (full details are shown
in Table 2). CoronaHiT-ONT had a higher pass rate
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compared to ARTIC LoCost even though the average
coverage was lower, this related to more even coverage
across samples on the flowcell (lower standard deviation
between samples relative to the mean—Table 1).
To assess the impact of data quality differences on
clustering of lineages, we built maximum likelihood trees
for both the routine and rapid response runs with each
of the 72 and 44 consensus genomes that passed QC
from the ARTIC LoCost, CoronaHiT-ONT and
CoronaHiT-Illumina sequencing experiments. When the
consensus genomes were placed on a phylogenetic tree
for the routine set, CoronaHiT-Illumina, ARTIC LoCost
and CoronaHiT-ONT showed the same clustering for
most samples, except for three cases (EB1DB, EC741
and EC644) where we note that their ARTIC LoCost
consensus show an increased number of ambiguous
bases. All variant differences between the samples are
noted in Additional file 1: Table S3, together with the
sequence length (discounting ambiguous bases whenever
there is a difference). Out of all samples in both datasets,
there were only two SNP discrepancies, one in sample
F04F8 between CoronaHiT-ONT and CoronaHiT-
Fig. 2 Ct value of the SARS-CoV-2 positive RNA samples sequenced using all three sequencing methods vs total number of Ns in the consensus
sequence for the a routine sample set b and the rapid response sample set
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Illumina, with ARTIC LoCost calling the SNP ambigu-
ous, and in sample F0A23 with CoronaHiT-ONT dis-
agreeing with the other methods (Additional file 1:
Table S3). The SNP differences did not affect the classi-
fication (i.e. closest sequence in the database), and there
were no SNP differences between ARTIC-ONT and
CoronaHiT-Illumina. The main other source of variation
between the samples is that the Illumina genomes allow
IUPAC [24] symbols for “partially” ambiguous bases.
These data show that CoronaHiT provides highly accur-
ate lineage calling compared to ARTIC LoCost.
The average number of SNPs between the Wuhan-
Hu-1 reference genome and the consensus genomes var-
ied between 7.99 SNPs for and 11.00 SNPs for the rou-
tine samples and 18.2 and 20.4 SNPs for the rapid
response samples across all methods (see Table 2 and
Additional file 1: Table S2a and S2b). The mean number
of SNPs in CoronaHiT-Illumina was higher compared to
the two ONT sequencing methods (Table 2) due to am-
biguous bases in the Illumina dataset being regarded as
SNPs in these calculations (Table 2).
The reagent cost per sample for CoronaHiT-ONT was
£8.46 when sequencing 95 samples and a negative con-
trol on a MinION flowcell, marginally cheaper but simi-
lar to ARTIC sequencing at £9.75 per sample (cost
breakdown in Additional file 1: Table S4). If 384 samples
are sequenced on an Illumina NextSeq Mid output run
with the CoronaHiT library preparation method, the per
sample cost is £6.22.
Discussion
Rapid viral genome sequencing during outbreaks is
changing how we study disease epidemiology [25, 26].
The recent SARS-CoV-2 global pandemic has again
highlighted the use of sequencing in the control of the
spread of the disease. Nanopore technology is particu-
larly suited to outbreak sequencing as it is portable, does
not require expensive machinery and is accessible
throughout the world [27]. We present a novel platform
agnostic method, CoronaHiT, for flexible throughput,
cost effective and low complexity sequencing of SARS-
CoV-2 genomes to respond to the pandemic at the local
and national level.
The ARTIC LoCost protocol [8] has been widely
adopted for SARS-CoV-2 genome sequencing and allows
up to 95 samples (plus a negative control) to be se-
quenced at a time on a MinION. CoronaHiT is just as
cheap, simple and fast, but the combination of transpo-
sase introduction of adapters with PCR based barcoding
allows for more even coverage between multiplexed
samples, resulting in a higher proportion of samples
passing QC. It is also designed to be platform agnostic,
simply switching barcodes to move to Illumina. This al-
lows the user to flexibly sequence low or high through-
put depending on rapidly changing requirements in the
pandemic. With the use of asymmetric barcode primers
[28], it is possible to sequence SARS-CoV-2 at very high
throughput on Illumina; in fact, we have recently se-
quenced over 1000 SARS-CoV-2 genomes on a single
Table 2 The number of samples passing and failing the different QC thresholds for each sequencing experiment













No. of samples sequenced 95 95 95 59 59 59
Consensus genomes 98.95% (94) 96.84% (92) 100% (95) 96.61% (57) 91.53% (54) 100% (59)
Passing COG-UK QC 80.00% (76) 76.84% (73) 82.11% (78) 81.36% (48) 74.58% (44) 81.36% (48)
Passing GISAID QC 69.47% (66) 62.11% (59) 77.89% (74) 74.58% (44) 67.80% (40) 74.58% (44)
Failing COG-UK QC 20.00% (19) 23.16% (22) 17.89% (17) 18.64% (11) 25.42% (15) 18.64% (11)
Failing GISAID QC 30.53% (29) 37.89% (36) 22.11% (21) 25.42% (15) 32.20% (19) 25.42% (15)
Avg. (median) Ns of COG-UK passed 1504 (354) 1635 (121) 688 (53) 977 (606) 1101 (339) 911 (292)
Avg SNPs of COG-UK passed 7.99 7.99 11.0 18.3 18.2 20.4
No. of samples with known Ct ≤ 32 65 65 65 18 18 18
Consensus genomes (Ct ≤ 32) 100% (65) 100% (65) 100% (65) 100% (18) 100% (18) 100% (18)
Passing COG-UK QC (Ct ≤ 32) 98.46% (64) 98.46% (64) 98.46% (64) 100%(18) 94.44% (17) 100% (18)
Passing GISAID QC (Ct ≤ 32) 95.38% (62) 89.23% (58) 98.46% (64) 94.44% (17) 88.89% (16) 94.44% (17)
Failing COG-UK QC (Ct ≤ 32) 1.54% (1) 1.54% (1) 1.54% (1) 0% (0) 5.56% (1) 0% (0)
Failing GISAID QC (Ct ≤ 32) 4.62% (3) 10.77% (7) 1.54% (1) 5.56% (1) 11.11% (2) 5.56% (1)
Avg (Median) Ns of COG-UK passed
(Ct ≤ 32)
682 (339) 815 (121) 111 (47) 895 (339) 911 (121) 1064 (514)
Avg SNPs of COG-UK passed (Ct ≤ 32) 8.19 8.17 10.2 18.8 18.9 20
Extended data are available in Additional file 1: Table S2a and S2b
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a
b
Fig. 3 Maximum likelihood tree of the consensus genomes from each sequencing methods, showing agreement between methods for the a
routine samples and b rapid response samples
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Illumina NextSeq High Output run using this approach
(data not shown). The CoronaHiT-Illumina library prep-
aration method is cheaper (reduced reaction volumes)
and significantly more streamlined (no sample washing
or quantification before pooling, no use of stop solution,
no clean-up after tagmentation and no clean-up of bar-
coded PCR products) than standard Illumina library
preparation.
Tiling PCR approaches, such as ARTIC, are prone to
high genome coverage variation due to variable primer
efficiency in multiplex reactions. Some regions of the
SARS-CoV-2 genome have hundreds of times higher
coverage than adjacent regions using ARTIC, therefore
average coverage of at least 1000X is required to obtain
at least 20X coverage of the difficult regions of the gen-
ome. We demonstrate that we can achieve > 1000X
SARS-CoV-2 genome coverage in ~ 20min per sample
using CoronaHiT-ONT on MinION, with a full set of 95
samples taking ~ 30 h. While the CoronaHiT-ONT runs
described here are very consistent, sequencing yield de-
pends on flowcell quality. We recommend aiming for at
least 100 Mbases of estimated sequencing yield per sam-
ple to provide sufficient data for > 1000X coverage/sam-
ple (average across flowcell) using CoronaHiT-ONT.
Results demonstrate that all methods are unreliable at
producing high quality consensus genomes from positive
clinical samples with diagnostic RT-qPCR Cts above 32
(approx. 100 viral genome copies); however, CoronaHiT
performs better in these samples (Fig. 2), producing fewer
Ns, likely due to the additional rounds of PCR during bar-
coding. Below or equal to Ct 32, CoronaHiT-ONT,
CoronaHiT-Illumina and ARTIC LoCost produce similar
results. While more samples pass both QC measures with
CoronaHiT-ONT and CoronaHiT-Illumina compared to
ARTIC LoCost, primer dropout regions can be more pro-
nounced in these methods (Additional file 2: Figures S1–
S6). For higher quality consensus genomes, sequencing
may be run for longer. Additionally, a reduction in ARTIC
PCR annealing temperature from 65 °C to 63 °C may help
improve coverage across these regions [23]. However, data
produced from CoronaHiT was sufficient to provide accur-
ate consensus genomes that result in the same lineages and
on the same branches on the phylogenetic tree as ARTIC
LoCost (Fig. 3). Therefore, we have demonstrated high
quality, multiplexed SARS-CoV-2 genome sequencing of
95 samples on a single flowcell. If the ARTIC PCR step is
optimised to even the coverage of the amplicons (as dem-
onstrated in the Sanger COVID-19 ARTIC Illumina proto-
col [23]), less overall coverage will be required per genome
and more samples can be multiplexed using all methods.
Conclusions
We demonstrate that CoronaHiT can be used to se-
quence 96 SARS-CoV-2 samples on a single MinION
flowcell, with the option of higher throughput on Illu-
mina. This platform agnostic method is simple, rapid
and cheap and results in more samples passing QC than
ARTIC LoCost while providing almost identical phylo-
genetic results. CoronaHiT can help scientists around
the world sequence SARS-CoV-2 genomes with highly
flexible throughput, thereby increasing our understand-
ing, and reducing the spread, of the pandemic.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13073-021-00839-5.
Additional file 1: Table S1. Barcode sequences. Table S2a. Sample
metrics for the Routine dataset. Table S2b. Sample metrics for the Rapid
Response dataset. Table S3. The differences between the consensus
genomes of each sequencing method, for all samples with differences
reported. Table S4. Reagent costs for the three methods when
sequencing 96 samples (CoronaHiT-ONT and ARTIC LoCost) or 384
samples (CoronaHiT-Illumina). Table S5. Sample identifiers and accession
numbers.
Additional file 2: Figures S1-S6. Overview of SARS-CoV-2 genome
coverage drop-out regions (Ns) of each sample that had a known Ct, for
the individual sequencing experiments: Figure S1. ARTIC LoCost for rou-
tine samples. Figure S2. CoronaHiT-ONT for routine samples. Figure S3
CoronaHiT-Illumina for routine samples. Figure S4. ARTIC LoCost for
rapid response samples. Figure S5. CoronaHiT-ONT for rapid response
samples. Figure S6. CoronaHiT-Illumina for rapid response samples.
Acknowledgements
Thanks to George Taiaroa and Torsten Seemann from the Microbiological
Diagnostic Unit Public Health Laboratory at the University of Melbourne for
their advice and assistance, to Niamh Tumelty from the University of
Cambridge for assistance and to Darren Heavens from the Earlham Institute
for his advice on library preparation. Thanks to the COG-UK Consortium
Study Group for their contributions.
Authors’ contributions
All authors have read this manuscript and consented to its publication. The
CoronaHiT method was developed by DJB and AA. The study was designed
and conceived by DJB, JOG and AJP. Paper writing was by DJB, AA, AJP, JOG,
GLK, APT, TLV, SR and LM. Sequencing and library preparation was
performed by DJB, AA, SR, GLK, APT, AB, AJT, NMT, RG and JOG.
Bioinformatics analysis and informatics were performed by TLV, LOM, NFA
and AJP. Clinical diagnostics and extractions were managed by AK, SD, RP,
NE and EM. Samples and metadata were collected by LG, AB, AVG, EMA, AK
and MD and biobanked by RS; RNA was extracted by AB and AJT. Risk
assessments were by GLK and JW. Project management and oversight was
by GLK, JOG, AJP, LM, MW, AEM and JW. Funding for the project was
secured by JOG, AJP and IGC.
Funding
The authors gratefully acknowledge the support of the Biotechnology and
Biological Sciences Research Council (BBSRC); this research was funded by
the BBSRC Institute Strategic Programme Microbes in the Food Chain BB/
R012504/1 and its constituent projects BBS/E/F/000PR10348, BBS/E/F/
000PR10349, BBS/E/F/000PR10351, and BBS/E/F/000PR10352. DJB, NFA, TLV
and AJP were supported by the Quadram Institute Bioscience BBSRC funded
Core Capability Grant (project number BB/CCG1860/1). EMA was funded by
the BBSRC Institute Strategic Programme Gut Microbes and Health BB/
R012490/1 and its constituent project(s) BBS/E/F/000PR10353 and BBS/E/F/
000PR10356. The sequencing costs were funded by the COVID-19 Genomics
UK (COG-UK) Consortium which is supported by funding from the Medical
Research Council (MRC) part of UK Research & Innovation (UKRI), the National
Institute of Health Research (NIHR) and Genome Research Limited, operating
as the Wellcome Sanger Institute. The author(s) gratefully acknowledge the
UKRI Biotechnology and Biological Sciences Research Council’s (BBSRC)
Baker et al. Genome Medicine           (2021) 13:21 Page 10 of 11
support of The Norwich Research Park Biorepository. LG was supported by a
DART MRC iCASE and Roche Diagnostics. APT was funded by Sara Borrell Re-
search Grant CD018/0123 from ISCIII and co-financed by the European De-
velopment Regional Fund (A Way to Achieve Europe program) and APT QIB
internship additionally funded by “Ayuda de la SEIMC”. The funders had no
role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Availability of data and materials
The consensus sequences were uploaded to GISAID (https://www.gisaid.org/)
and the raw sequence data was uploaded to the European Nucleotide
Archive (https://www.ebi.ac.uk/ena/browser/home) under BioProject
PRJEB41737. The accession numbers for each sample are available in
Additional file 1: Table S5.
Ethics approval and consent to participate
The COVID-19 Genomics UK Consortium has been given approval by Public
Health England’s Research Ethics and Governance Group (PHE R&D Ref:
NR0195). Written informed consent was not required as only excess diagnos-
tic samples were used and no patient identifiable information was collected





LG received a partial support for his PhD from Roche. The use of Roche
technology for diagnostics in NNUH is coincidental. The authors declare that
they have no competing interests.
Author details
1Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UQ,
UK. 2Grupo de Investigación Biomédica en Sepsis - BioSepsis. Hospital
Universitario Rio Hortega/Instituto de Investigación Biomédica de Salamanca
(IBSAL), Valladolid/Salamanca, Spain. 3Norfolk and Norwich University
Hospital, Colney Lane, Norwich NR4 7UY, UK. 4University of East Anglia,
Norwich Research Park, Norwich NR4 7TJ, UK.
Received: 7 July 2020 Accepted: 26 January 2021
References
1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track
COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4.
2. Shu Y, McCauley J. GISAID: global initiative on sharing all influenza data –
from vision to reality. Eurosurveillance. 2017;22(13):30494.
3. COVID-19 Genomics UK Consortium. COVID-19 Genomics UK
Consortium [Internet]. [cited 2021 Jan 22]. Available from: https://www.
cogconsortium.uk/.
4. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus
associated with human respiratory disease in China. Nature. 2020;579(7798):
265–9.
5. ARTIC Network. ARTIC Network - real-time molecular epidemiology for
outbreak response [Internet]. [cited 2021 Jan 22]. Available from: https://
artic.network/.
6. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s
innovative contribution to global health. Global Chall. 2017;1(1):33–46.
7. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al.
Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;
34(23):4121–3.
8. Quick J. nCoV-2019 sequencing protocol v3 (LoCost). 2020 [cited 2021 Jan
22]; Available from: https://www.protocols.io/view/ncov-2019-sequencing-
protocol-v3-locost-bh42j8ye.
9. ARTIC Network. ARTIC nanopore protocol for nCoV2019 novel coronavirus
[Internet]. GitHub. [cited 2021 Jan 22]. Available from: https://github.com/
artic-network/artic-ncov2019.
10. Rowan BA, Heavens D, Feuerborn TR, Tock AJ, Henderson IR, Weigel D. An
ultra high-density Arabidopsis thaliana crossover map that refines the
influences of structural variation and epigenetic features. Genetics. 2019;
213(3):771–87.
11. Beier S, Himmelbach A, Colmsee C, Zhang X-Q, Barrero RA, Zhang Q, et al.
Construction of a map-based reference genome sequence for barley,
Hordeum vulgare L. Scientific Data. 2017;4(1):170044.
12. Le-Viet T. Configuration for demultiplexing coronaHiT data with Guppy
[Internet]: Quadram Institute Bioscience; 2020. [cited 2021 Jan 22]. Available
from: https://github.com/quadram-institute-bioscience/coronahit_guppy
13. Loman NJ, Rowe W, Rambaut A. nCoV-2019 novel coronavirus
bioinformatics protocol [Internet]. 2020 [cited 2021 Jan 22]. Available from:
https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html
14. Loman N, ZiBRA Project, ARTIC Project. The ARTIC field bioinformatics
pipeline [Internet]. GitHub. [cited 2021 Jan 22]. Available from: https://
github.com/quadram-institute-bioscience/fieldbioinformatics.
15. Bull M, Pathogen Genomics Unit, PHW Microbiology. ARTIC Nanopore+
Illumina Nextflow Pipeline [Internet]. GitHub. [cited 2021 Jan 22]. Available
from: https://github.com/quadram-institute-bioscience/ncov2019-artic-nf.
16. Krueger F. TrimGalore [Internet]. [cited 2021 Jan 22]. Available from: https://
github.com/FelixKrueger/TrimGalore.
17. Li H. Aligning sequence reads, clone sequences and assembly contigs with
BWA-MEM. arXiv. 2013:13033997 [q-bio] [Internet]. [cited 2021 Jan 22];
Available from: http://arxiv.org/abs/1303.3997.
18. Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ,
et al. An amplicon-based sequencing framework for accurately measuring
intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 2019;20(1):8.
19. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von
Haeseler A, et al. IQ-TREE 2: new models and efficient methods for
phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37(5):1530–4.
20. Hasegawa M, Kishino H, Yano T. Dating of the human-ape splitting by a
molecular clock of mitochondrial DNA. J Mol Evol. 1985;22(2):160–74.
21. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-
sites: rapid efficient extraction of SNPs from multi-FASTA alignments.
Microbial Genomics. 2016;2(4):e000056.
22. Rambaut A. FigTree [Internet]. [cited 2021 Jan 22]. Available from: https://
github.com/rambaut/figtree.
23. DNA Pipelines R&D, Farr B, Rajan D, Betteridge E, Shirley L, Quail M, et al.
COVID-19 ARTIC v3 Illumina library construction and sequencing protocol.
2020 [cited 2021 Jan 22]; Available from: https://www.protocols.io/view/
covid-19-artic-v3-illumina-library-construction-an-bgq3jvyn.
24. IUPAC-IUB Comm. on Biochem. Nomenclature (CBN). Abbreviations and
symbols for nucleic acids, polynucleotides, and their constituents.
Biochemistry. 1970;9(20):4022–7.
25. Kafetzopoulou LE, Pullan ST, Lemey P, Suchard MA, Ehichioya DU, Pahlmann
M, et al. Metagenomic sequencing at the epicenter of the Nigeria 2018
Lassa fever outbreak. Science. 2019;363(6422):74.
26. Quick J, Loman NJ, Duraffour S, Simpson JT, Severi E, Cowley L, et al. Real-
time, portable genome sequencing for Ebola surveillance. Nature. 2016;
530(7589):228–32.
27. Faria NR, Sabino EC, Nunes MRT, Alcantara LCJ, Loman NJ, Pybus OG.
Mobile real-time surveillance of Zika virus in Brazil. Genome Med. 2016;
8(1):97.
28. Perez-Sepulveda BM, Heavens D, Pulford CV, Predeus AV, Low R, Webster H,
et al. An accessible, efficient and global approach for the large-scale
sequencing of bacterial genomes. bioRxiv. 2020; 2020.07.22.200840.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Baker et al. Genome Medicine           (2021) 13:21 Page 11 of 11
